Skip to content
Evigrade
MajorAtypical antipsychotic – dibenzodiazepine×Macrolide antibiotic

Updated · Methodology

Mechanism

Erythromycin and clozapine both prolong the QT interval on the electrocardiogram and can cause torsade de pointes, other life-threatening ventricular arrhythmias and sudden death (erythromycin labels; US clozapine label, Food and Drug Administration, FDA). The US clozapine label lists erythromycin both among drugs that prolong the QT interval and among drugs that inhibit clozapine metabolism. The liver breaks down clozapine through the enzymes CYP1A2, CYP2D6 and CYP3A4. Erythromycin inhibits CYP3A4, and reduced clozapine clearance with a stronger clozapine effect has been reported with the combination (Spanish erythromycin label). According to the Spanish clozapine label, CYP1A2 inhibitors raise clozapine levels the most. A relevant effect of erythromycin and other CYP3A4 inhibitors is unlikely, although some cases have been reported. Pneumonia and other inflammatory conditions for which an antibiotic is prescribed may raise clozapine levels on their own (US clozapine label, FDA).

Symptoms

QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes and other ventricular arrhythmias present as palpitations, dizziness, presyncope or syncope (US clozapine label, Food and Drug Administration, FDA). Higher clozapine levels bring more drowsiness, dizziness, a drop in blood pressure on standing up that can end in fainting, and a fast heart rate. The risk of seizures with clozapine rises with the dose (clozapine label). The risk of arrhythmia is higher with low potassium or magnesium, bradycardia, severe heart failure, conduction disorders and in older people (erythromycin labels and US clozapine label).

Management

The Spanish label of one intravenous erythromycin product (Panpharma, registration number 79380) lists use with certain QT-prolonging neuroleptics among its contraindications. The labels of the original intravenous product and of oral forms ask only for caution with such drugs (erythromycin labels, Spanish Agency of Medicines and Medical Devices, AEMPS). Clozapine falls under this wording: QT prolongation, torsade de pointes, cardiac arrest and sudden death have occurred with clozapine treatment (US clozapine label, Food and Drug Administration, FDA), and the clozapine labels call for caution with QT-prolonging drugs (clozapine labels). Erythromycin is contraindicated in patients with a history of QT prolongation or ventricular arrhythmia and in those with low potassium or magnesium (erythromycin labels). Check and correct potassium and magnesium and consider an electrocardiogram (ECG) before starting the combination (US clozapine label). Stop clozapine if the corrected QT interval (QTc) exceeds 500 ms (US clozapine label). If syncope, presyncope, dizziness or palpitations occur, obtain a cardiac evaluation and stop clozapine (US clozapine label). While the patient takes erythromycin, watch for clozapine adverse effects and consider a lower clozapine dose if they appear (clozapine labels). When the course of erythromycin ends, clozapine levels may fall, so keep monitoring (Spanish clozapine label). According to the Spanish clozapine label, fever or signs of infection in a patient taking clozapine call for an immediate absolute neutrophil count (ANC). Persistent resting tachycardia, chest pain or shortness of breath raise suspicion of myocarditis: stop clozapine promptly and refer the patient to a cardiologist at once (Spanish clozapine label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Clozapine

Other interactions with Erythromycin